Insights

  • Home
  • Insights
  • Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

Share

Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, <i>PTAB Litigation Blog</i>

Genentech to Defend 3 of 4 Herceptin® Patents Challenged by Hospira, PTAB Litigation Blog

August 09, 2017 Blog

Visit the Jones Day PTAB Litigation Blog.

At least 19 IPRs have been filed against seven of Genentech’s patents covering its blockbuster antibody drug Herceptin® (trastuzumab). On July 27, 2017, the PTAB instituted IPRs filed by Hospira, Inc. (a subsidiary of Pfizer) against three Herceptin® patents, and denied an IPR for a fourth Herceptin® patent.

The four challenged patents (U.S. Patent Nos. 6,627,196; 7,371,379; 7,846,441; and 7,892,549) belong to two different families, with one family covering the use of Herceptin® in combination therapies and the other covering dosing regimens for treating disorders characterized by overexpression of ErbB2.

Read the full article at ptablitigationblog.com.

You May Also Be Interested In

December 20, 2024 Alert

New Year, New Fees: USPTO Surcharges and Fee Increases for Trademark Filings in 2025

December 20, 2024 Blog

PTAB Reiterates Strict Evidentiary Standard for Printed Publications, PTAB Litigation Blog

December 19, 2024 Commentary

French CSPLA Report Highlights AI Regulation: Transparency and Copyright Compliance in Focus

December 19, 2024 Commentary

Trademark Scams 101: Common Signs of Scams and How to Avoid Them

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.